Market research
OSL.AU OncoSil Medical Limited
AU AUD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 26M
- P/E ratio
- Not available
- Analyst target
- 0.06
- Dividend yield
- Not available
- Beta
- 1.31
Profile
Company facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- AU000000OSL3
- Market cap
- 26M
- P/E ratio
- Not available
- Analyst target
- 0.06
- Dividend yield
- Not available
- Beta
- 1.31
About
About OncoSil Medical Limited
OncoSil Medical Limited, a medical device company, develops and commercializes localised radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The company offers OncoSil, a single-use brachytherapy device for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the OSL.AU discussion.
5 years, 6 months ago
OncoSil Medical Limited is currently in a long term downtrend where the price is trading 42.9% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
OncoSil Medical Limited's total revenue sank by 32.3% to $829K since the same quarter in the previous year.
Its net income has dropped by 39.5% to $-5M since the same quarter in the previous year.
Finally, its free cash flow fell by 220.9% to $-2M since the same quarter in the previous year.
Based on the above factors, OncoSil Medical Limited gets an overall score of 1/5.